TARA-002 Shows 55% Complete Response Rate at 12 Months in Phase 2 NMIBC Trial, Registrational Study Planned
TARA sits 95% above its 52-week low of $2.77.
Summary
Protara Therapeutics announced positive updated 12-month data from the fully enrolled BCG-naïve cohort of its Phase 2 ADVANCED-2 trial for TARA-002 in non-muscle invasive bladder cancer (NMIBC). The data demonstrated durable responses, with a 55% complete response rate at the 12-month landmark, following a 67% CRR at 6 months and 72% at any time. TARA-002 also exhibited a favorable safety and tolerability profile. This strong clinical data is a significant positive catalyst for the company, confirming the drug's efficacy and safety profile. The company is now on track to initiate the ADVANCED-3 registrational trial in BCG-naïve patients in the second half of 2026, a critical step towards potential market approval. This news provides specific, positive clinical details that were not fully disclosed in the recent Q1 earnings update.
At the time of this announcement, TARA was trading at $5.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.9M. The 52-week trading range was $2.77 to $7.82. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.